Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute – spotlights key breast oncology updates from ESMO25.
“1 mg/kg of Pembrolizumab saturates PD1. Could we give a lower dose and reduce financial toxicity? In the PLANeT randomized phase 2 trial, low-dose Pembrolizumab (50 mg for 3 Q6W doses) added to neoadjuvant ddAC-T significantly improved pCR for stage II-III TNBC (delta 13%).”
“Discussion by Theodoros Foukakis:
Impressively similar benefit of low-dose Pembrolizumab in KN522 and PLANeT- yet the latter was a small phase 2 trial, hypothesis-generating rather than practice-changing. MANY pending questions in the field of neoadjuvant IO for TNBC. A lot of work is needed.”
“Long-term outcomes from POSITIVE (71 mo follow-up)
‘We could demonstrate that, with long follow-up, interrupting ET to achieve pregnancy and resuming ET, does not lead to increased risk of recurrence from breast cancer.’
Fedro Peccatori
Total of 442 births.
“One of the highlights of ESMO25:
Adjuvant Abemaciclib significantly improves OS in high-risk ER+ eBC (1.8% OS delta at 7 years).
Benefit is enriched in premenopausal pts and those with more than 10 positive nodes. Updated iDFS curves denote persistent benefit. Practice-confirming.”
“Updated, 5-year results from NATALEE:
3 years of adjuvant ribo show continued improvement in iDFS, with a 5-year delta of 4.5%. Benefit observed in N+ and N0 patients (who were not eligible for Abemaciclib). Promising OS trend, with a similar delta to monarchE.”
“How do adjuvant CDK4/6i impact the biology of breast cancer that recurs? Angie DeMichele highlights our RW study, led by Chiara Corti, which found 50% of patients losing ER expression and having short 1L PFS if relapsing after Abemaciclib.
Published in ESMO Open.”
More posts featuring Paolo Tarantino on OncoDaily.
